
GeneDx Holdings Corp. Class A Common Stock
WGS
WGS: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.
moreShow WGS Financials
Recent trades of WGS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by WGS's directors and management
Government lobbying spending instances
-
$17,500 May 15, 2023 Issue: Medical/Disease Research/Clinical Labs
-
$17,500 Oct 17, 2022 Issue: Medical/Disease Research/Clinical Labs
-
$35,000 Apr 20, 2022 Issue: Medical/Disease Research/Clinical Labs
New patents grants
Federal grants, loans, and purchases
Followers on WGS's company Twitter account
Number of mentions of WGS in WallStreetBets Daily Discussion
Recent insights relating to WGS
Recent picks made for WGS stock on CNBC
ETFs with the largest estimated holdings in WGS
Flights by private jets registered to WGS